Geoffrey Chupp, MD
Professor of Medicine
Director, Yale Center for Asthma and Airways Disease
Pulmonary, Critical Care, and Sleep Medicine
Yale School of Medicine
Director, Pulmonary Function Laboratory
Yale-New Haven Hospital
New Haven, Connecticut
Njira Lucia Lugogo, MD, MS
Associate Professor of Internal Medicine
Asthma Program Director
Division of Pulmonary & Critical Care Medicine
University of Michigan Pulmonary & Critical Care Medicine
Ann Arbor, Michigan
Michael E. Wechsler, MD, MMSc
Professor, Department of Medicine
Director, The Cohen Family Asthma Institute
Division of Pulmonary, Critical Care and Sleep Medicine
Director, Asthma Program
National Jewish Health
Denver, Colorado

Program Description  

Severe asthma has been clearly tied to significant medical, psychological, social, and economic risks and burdens for affected patients and their families. Despite the clear need for comprehensive and intensive management, substantial gaps in patient care persist. This live Expert Roundtable—with 3 internationally recognized asthma experts who have extensive experience in clinical research, patient care, and clinician education—will cover key clinical issues involving the use of biologics in severe asthma. Topics will include, but not be limited to, patient selection and timely initiation of biologics; underlying mechanisms of disease and characteristic phenotypes that can help guide biologic selection; and recommendations for managing common challenges, such as achieving asthma control, OCS weaning, treatment failure, biologic switching, and mitigating treatment side effects.

Target Audience  

The educational design of this activity addresses the needs of pulmonologists, clinical immunologists/allergists, and other specialist clinicians who manage patients with severe asthma. 

Educational Objectives 

After completing this activity, the participant should be better able to:  

  • Discuss upstream pathophysiologic processes that contribute to airway hyperresponsiveness, mucus plugging, and airway remodeling, including implications for asthma treatment 
  • Describe the clinical profiles and evidence for biologic therapies to address various aspects of severe asthma pathophysiology 
  • Tailor treatment regimens for severe asthma to account for underlying disease processes and overcome barriers related to the use of biologics 

Physician Accreditation Statement 

Integritas Communications is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

Physician Credit Designation

Integritas Communications designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must:

  1. Read the educational objectives, accreditation information, and faculty disclosures at the beginning of this activity.
  2. Complete the Preactivity Questions.
  3. Review the activity content.
  4. Achieve a grade of at least 70% on the Postactivity Test Questions and complete the Evaluation.

Disclosures of Conflicts of Interest

Integritas Communications adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content are required to disclose all financial relationships with any ineligible company within the past 24 months to Integritas. All financial relationships reported are identified as relevant and mitigated by Integritas in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Integritas to assure objectivity and that the activity is free of commercial bias. 

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Geoffrey Chupp, MD: Consulting fees: AstraZeneca plc, GSK plc, Regeneron Pharmaceuticals, Inc., Sanofi Genzyme, RAPT Therapeutics, Inc., Merck & Co., Inc., Genentech, Inc.; Contracted Research: AstraZeneca plc, GSK plc, Regeneron Pharmaceuticals, Inc.

Njira L. Lugogo, MD, MS: Consulting fees: Amgen, Inc., AstraZeneca plc, Avillion LLP, Genentech, Inc., GSK plc, Nioxx, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd.; Contracted Research: Institution received research support from Amgen, Inc., AstraZeneca plc, Avillion LLP, Evidera, Genentech, Inc., Gossamer Bio, GSK plc, Janssen Pharmaceuticals, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd.; Honoraria: AstraZeneca plc, GSK plc; Travel Support: AstraZeneca plc

Michael E. Wechsler, MD, MMSc: Consulting Fees: Amgen, Inc., Areteia Therapeutics, Inc., AstraZeneca plc, Avalo Therapeutics, Inc., Boehringer Ingelheim International GmbH, Celldex Therapeutics, Inc., Cohero Health, Inc., CytoReason LTD, Eli Lilly and Company, Equillium, Foresite Labs, Genentech, Inc., GSK plc, Incyte Corporation, Kinaset Therapeutics, Inc., Merck & Co., Inc., Novartis Pharmaceuticals Corporation, OM Pharma SA, Phylaxis Bioscience, LLC, PULMATRiX, Inc., RAPT Therapeutics, Inc., Regeneron Pharmaceuticals, Inc., resTORbio, Inc., Sanofi S.A., Sentien Biotechnologies, Inc., Sound Biologics, Tetherex Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Upstream Bio, Inc.

The Integritas Communication planners and managers have no relevant financial relationships to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Integritas Communications does not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Integritas Contact Information

For questions about this activity, please contact us at info@exchangecme.com.

Begin Activity
available resources
meeting slides
interactive presentation
linked resources
Suggested Reading
Expert Roundtable

An Expert Panel on Severe Asthma

From the Epithelium to Better Patient Outcomes